Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Phase 2 Completed

82 enrolled 13 charts

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT02588651 2025-11-21

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Phase 2 Completed

23 enrolled 15 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT01508312 2025-10-21

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

66 enrolled 14 charts

Lymphoid

Hodgkin Disease

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Phase 2 Completed

71 enrolled

Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Phase 2 Completed

26 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT02388490 2024-09-23

Bretuximab

Phase 2 Completed

25 enrolled 12 charts

Lymphoid

Lymphoma, Recurrence

NCT02191930 2024-08-23

BVB

Phase 2 Completed

70 enrolled

Lymphoid

Hodgkin Disease

NCT03217643 2024-06-20

EATL-001

Phase 2 Completed

14 enrolled

Lymphoid

Enteropathy-Associated T-Cell Lymphoma

NCT02398240 2023-10-26

Brentuximab for Newly Diagnosed Hodgkin Disease

Phase 2 Completed

40 enrolled

Lymphoid

Hodgkin Disease

NCT02292979 2022-08-19

BREACH

Phase 2 Completed

170 enrolled

Lymphoid

Hodgkin Disease

NCT02298283 2021-07-26

BRAPP2

Phase 2 Completed

40 enrolled

Lymphoid

Hodgkin Disease

NCT02939014 2021-02-24

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Phase 2 Completed

39 enrolled 26 charts

Lymphoid

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT02227433 2020-12-22

FIL_BVHD01

Phase 2 Completed

20 enrolled

Lymphoid

Hodgkin Disease

NCT02505269 2020-08-24

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Phase 2 Completed

34 enrolled 7 charts

Lymphoid

Hodgkin Disease

NCT01807598 2019-01-29

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Phase 2 Completed

10 enrolled 14 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT01569204 2018-10-29

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Phase 2 Completed

100 enrolled

Lymphoid

Hodgkin Disease

NCT02280785 2018-09-06

BRAN

Phase 2 Completed

33 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT02567851 2018-05-11

BREVITY

Phase 2 Completed

38 enrolled

Lymphoid

Hodgkin Disease, Lymphoma

NCT01393717 2018-04-26

Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

Phase 2 Completed

57 enrolled 14 charts

Lymphoid

Hodgkin Disease

NCT01534078 2018-02-20

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Phase 2 Completed

34 enrolled 15 charts

Lymphoid

Hodgkin Disease

NCT02244021 2018-02-09

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

Phase 2 Completed

13 enrolled

Lymphoid

Hodgkin Disease

NCT01851200 2018-02-07

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Phase 2 Completed

9 enrolled

Genitourinary

Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal

NCT01396070 2017-04-05

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

Phase 2 Completed

36 enrolled 13 charts

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00866047 2017-03-22

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

Phase 2 Completed

58 enrolled 19 charts

Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT00947856 2017-02-02

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

Phase 2 Completed

110 enrolled 15 charts

Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT01421667 2016-11-28

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 2 Completed

176 enrolled 30 charts

Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01461538 2016-03-04

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Phase 2 Completed

84 enrolled 20 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00337194 2015-02-23

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

30 enrolled 13 charts

Lymphoid

Hodgkin Disease

NCT00079755 2014-12-18

Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma

Phase 2 Completed

80 enrolled

Lymphoid

Lymphoma, Lymphoma, Large-Cell, Anaplastic

NCT00099255 2014-12-18

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Phase 2 Completed

40 enrolled

DermatologicLymphoidSarcoma

Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Clinical Trials

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Bretuximab

BVB

EATL-001

Brentuximab for Newly Diagnosed Hodgkin Disease

BREACH

BRAPP2

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

FIL_BVHD01

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

BRAN

BREVITY

Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma